Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by InSightec
Information provided by (Responsible Party):
InSightec Identifier:
First received: April 12, 2013
Last updated: September 12, 2016
Last verified: September 2016
The study hypotheses is that the proportion of patients experiencing clinically significant pain relief will be at least 30% greater than the proportion experiencing worsening pain.

Condition Intervention
Bone Metastasis
Device: ExAblate MRgFUS

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain

Resource links provided by NLM:

Further study details as provided by InSightec:

Primary Outcome Measures:
  • Proportion of Responders [ Time Frame: Three months ]
    The statistical hypothesis is that the proportion of responders will be significantly greater than the proportion of subjects experiencing pain progression (worsened pain or increased pain medications usage) by at least 30% or an odds ratio of at least 2.

Secondary Outcome Measures:
  • Safety Profile [ Time Frame: Three Months ]
    A full safety profile will be developed for the ExAblate treatment of bone metastases. All adverse events will be captured and summarized as defined in Section-6.2. Adverse events (type, frequency, severity) are expected to be similar to those captured for the original PMA study (PMA # P110039). For his study, the Safety comparison will be descriptive with no statistical endpoints.

Other Outcome Measures:
  • Pain Interference [ Time Frame: Three Months ]
    Patient overall quality of life status will be assessed by the BPI-QoL Pain Interference scale which will be administered pre-treatment and post-treatment. The trajectory of change may be analyzed descriptively by regression slopes.

Estimated Enrollment: 70
Study Start Date: September 2013
Estimated Study Completion Date: October 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ExAblate Test Arm
Focused Ultrasound Surgery delivered by ExAblate MRgFUS
Device: ExAblate MRgFUS
Focused Ultrasound Ablation
Other Name: Magnetic Resonance guided Focused Ultrasound Surgery

Detailed Description:

As part of the PMA # P110039 review process and approval, InSightec was requested to conduct a post-approval study. Patients will be treated following the approved commercial treatment guidelines.

For this study, participating sites will use the ExAblate device for the administration of the ExAblate treatment. This study will be performed on either 1.5T or 3T MR scanners.

For this study, a total of 70 patients meeting the approved commercial guidelines will be enrolled and treated with the ExAblate system at from 7 to 10 sites. The proportion of responders is expected to be at least 30% greater than the proportion of subjects experiencing pain progression (i.e., 60% vs. 30%). Additionally, at the 3 month visit, an analysis of both the safety and efficacy profiles will be compared to the original PMA pivotal study group.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women age 18 and older
  • Patients who are able and willing to give consent and able to attend all study visits
  • Patients who are suffering from symptoms of bone metastases or multiple myeloma bone lesions:
  • Patients who have received radiation without adequate relief from metastatic bone pain as determined by the patient and treating physician
  • those for whom their treating physician would not prescribe radiation or additional radiation treatments
  • patients who refuse additional radiation therapy.
  • Patient with NRS (0-10 scale) pain score ≥ 4 irrespective of medication
  • Targeted bone/tumor interface are ExAblate device accessible and are located in ribs, extremities (excluding joints), pelvis, shoulders and in the posterior aspects of the following spinal vertebra: Lumbar vertebra (L3 - L5), Sacral vertebra (S1 - S5)
  • Targeted bone/tumor interface (most painful lesion) size up to 55 cm2 in surface area
  • Patient whose targeted (treated) lesion is on bone and the interface between the bone and lesion is deeper than 10-mm from the skin.
  • Targeted (treated) tumor clearly visible by non-contrast MRI, and ExAblate MRgFUS device accessible
  • Able to communicate sensations during the ExAblate treatment
  • Patients on ongoing chemotherapy regimen at the time of eligibility:

    1. with same chemotherapy regime (as documented from patient medical dossier), And
    2. Worst pain NRS still ≥ 4 And
    3. do NOT plan to initiate a new chemotherapy for pain palliation should be eligible for the study.

Note: Planned multiple courses of chemotherapy are not considered New Chemotherapy.

  • No radiation therapy to targeted (most painful) lesion in the past two weeks Bisphosphonate intake should remain stable throughout the study duration.
  • Patients will have from 1 to 5 painful lesions and only the most painful lesion will be treated.
  • Patients with persistent distinguishable pain associated with 1 site to be treated (if patient has pain from additional sites, the pain from the additional sites must be evaluated as being less intense by at least 2 points on the NRS compared to the site to be treated).

Exclusion Criteria:

  • Patients who either
  • Need surgical stabilization of the affected bony structure (>7 fracture risk score, see Section 7.4) OR
  • Targeted tumor is at an impending fracture site (>7 on fracture risk score, see Section 7.4).


  • Patients with surgical stabilization of tumor site with metallic hardware
  • More than 5 painful lesions, or more than 1 requiring immediate localized treatment
  • Targeted (treated) tumor is in the skull
  • Patients on dialysis
  • Patients with life expectancy < 3-Months
  • Patients with an acute medical condition (e.g., pneumonia, sepsis) that is expected to hinder them from completing this study.
  • Patients with unstable cardiac status including:
  • Unstable angina pectoris on medication
  • Patients with documented myocardial infarction within six months of protocol entry
  • Congestive heart failure requiring medication (other than diuretic)
  • Patients on anti-arrhythmic drugs
  • Severe hypertension (diastolic BP > 100 on medication)
  • Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.
  • Patients with an active infection or severe hematological, neurological, or other uncontrolled disease.
  • Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or Magnevist) including advanced kidney disease
  • KPS Score < 60 (See "Definitions" below)
  • Severe cerebrovascular disease (multiple CVA or CVA within 6 months)
  • Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (approximately 2 hrs.)
  • Target (treated) tumor is less then 1cm from nerve bundles, bowels or bladder.
  • Are participating or have participated in another clinical trial in the last 30 days
  • Patients initiating a new chemotherapy regime for pain purposes only, or radiation (for the targeted most painful lesion) within the last 2 weeks Note: Planned multiple courses of chemotherapy are not considered New Chemotherapy.
  • Patients unable to communicate with the investigator and staff.
  • Patients with persistent undistinguishable pain (pain source unidentifiable of the targeted lesion)
  • Patient whose bone-lesion interface is < 10-mm from the skin
  • Targeted (most painful) tumor NOT visible by non-contrast MRI,
  • Targeted (most painful) tumor Not accessible to ExAblate
  • The targeted tumor is less than 2 points more painful compared to other painful lesions on the site specific NRS.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01833806

United States, California
City of Hope Recruiting
Duarte, California, United States, 91010
Contact: Bianca Del Vecchio    626-256-4673 ext 64402   
Principal Investigator: Jeff Wong, MD         
University of California San Francisco Recruiting
San Francisco, California, United States, 94107
Contact: Stephanie Murphy    415-353-9446   
Principal Investigator: Thomas Link, M.D.         
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Pam Gallant    650-736-8965   
Principal Investigator: Pejman Ghanouni, MD         
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Connie Sathre    507-538-0540   
Principal Investigator: David Woodrum, MD         
United States, New York
Weill Cornell Medical Center Recruiting
New York, New York, United States, 10065
Contact: Jamie Stern    212-746-9748   
Principal Investigator: David Li, MD, PhD         
United States, Pennsylvania
Fox Chase Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19111
Contact: Joan Leahy    215-728-2994   
Principal Investigator: Joshua Meyer, MD         
United States, Texas
MD Anderson Completed
Houston, Texas, United States, 77030
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Parchayi Dalal   
Principal Investigator: James Larner, MD         
Sponsors and Collaborators
  More Information

Responsible Party: InSightec Identifier: NCT01833806     History of Changes
Other Study ID Numbers: BM018
P110039/S2 ( Other Identifier: FDA PMA Supplement )
Study First Received: April 12, 2013
Last Updated: September 12, 2016 processed this record on April 24, 2017